Ocular Therapeutix Inc

OCUL's active lockout rally underpins a medium-term bullish bias, with price pulling back into the rising EMAs within a key support zone. Short-interest squeeze dynamics support forced participation, and the long-term uptrend remains intact above the 200-SMA. The current pullback offers a favorable entry point for continuation participation, while failure to hold EMAs or volume follow-through would warrant caution.

• ↑Expect AXPAXLI NDA submission in Q4 2026, leveraging positive SOL-1 Week 52 data
• ↑Cash runway of $598.6M extends funding into 2028 for trials and launch
• ↓Q2 net loss of $78.8M ($0.35/share) on flat $13.5M revenue